Combining 5AZA-CdR and HDAC Inhibitors for Ewing's Sarcoma Treatment
Author Information
Author(s): Annie Hurtubise, Mark L Bernstein, Richard L Momparler
Primary Institution: Département de pharmacologie, Université de Montréal
Hypothesis
Does the combination of 5-aza-2'-deoxycytidine and histone deacetylase inhibitors enhance antineoplastic activity against Ewing's sarcoma cells?
Conclusion
The combination of 5AZA-CdR and MS-275 shows significant potential for treating advanced Ewing's sarcoma by reactivating tumor suppressor genes.
Supporting Evidence
- 5AZA-CdR reactivates silenced tumor suppressor genes.
- HDAC inhibitors enhance the antineoplastic action of 5AZA-CdR.
- The combination of 5AZA-CdR and MS-275 showed marked synergy.
- The study suggests further clinical investigation of this combination.
Takeaway
This study found that using two types of cancer-fighting drugs together can work better than using them alone to help treat a specific type of cancer called Ewing's sarcoma.
Methodology
The study used clonogenic assays to evaluate the antineoplastic activity of 5AZA-CdR combined with various HDAC inhibitors on Ewing's sarcoma cell lines.
Statistical Information
P-Value
p < 0.01
Statistical Significance
p < 0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website